FCN 011
Alternative Names: FCN-011Latest Information Update: 28 May 2024
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (PO)
- 13 Apr 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04687423)
- 29 Dec 2020 Chongqing Fochon Pharmaceutical plans a phase I/II trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (PO) in December 2020 (NCT04687423)